Halozyme
HALO
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 350
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
24% more call options, than puts
Call options by funds: $26.3M | Put options by funds: $21.3M
10% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 80
0% less funds holding
Funds holding: 542 [Q1] → 541 (-1) [Q2]
3.25% less ownership
Funds ownership: 97.48% [Q1] → 94.23% (-3.25%) [Q2]
18% less repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 214
21% less capital invested
Capital invested by funds: $7.68B [Q1] → $6.04B (-$1.64B) [Q2]
67% less funds holding in top 10
Funds holding in top 10: 9 [Q1] → 3 (-6) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Morgan Stanley
Vikram Purohit
|
$80
|
Overweight
Maintained
|
18 Aug 2025 |
|
JP Morgan
Jessica Fye
|
$63
|
Neutral
Maintained
|
7 Aug 2025 |
|
JMP Securities
Jason N. Butler
|
$91
|
Market Outperform
Maintained
|
6 Aug 2025 |
|
HC Wainwright & Co.
Mitchell Kapoor
|
$75
|
Buy
Maintained
|
6 Aug 2025 |
Financial journalist opinion
Based on 14 articles about HALO published over the past 30 days
